查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1795369

穩定同位素標記生物分子的全球市場

Stable Isotope Labeled Biomolecules
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 169 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

預計到 2030 年，全球穩定同位素標記生物分子市場規模將達到 5.17 億美元

2024年，全球穩定同位素標記生物分子市場規模估計為3.711億美元，預計到2030年將達到5.17億美元，在2024-2030年的分析期內，複合年成長率為5.7%。 D標記生物分子是本報告分析的細分市場之一，預計其複合年成長率為5.4%，到分析期結束時達到3.08億美元。 15N標記生物分子細分市場在分析期間的複合年成長率估計為6.6%。

美國市場規模估計為 9,760 萬美元，中國市場預計複合年成長率為 5.5%

美國穩定同位素標記生物分子市場規模預計在2024年達到9,760萬美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到8,290萬美元，在2024-2030年的分析期間內，複合年成長率為5.5%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個國家的複合年成長率分別為5.0%和4.9%。在歐洲，預計德國的複合年成長率為4.6%。

全球穩定同位素標記生物分子市場－主要趨勢與促進因素摘要

是什麼推動了穩定同位素標記生物分子研究的成長？

穩定同位素標記的生物分子，包括13C、15N和2H標記的胺基酸、核苷酸、脂質和代謝物，是蛋白質體學、代謝體學、藥物動力學和示蹤研究的重要工具。它們可用於質譜分析、同位素稀釋定量、MRI成像劑、細胞示蹤實驗和代謝通量分析。主要終端使用者包括學術實驗室、藥物研發、生物製造品質控制和石化測試。

諸如精確定量、通路圖譜繪製和品質保證等複雜工作流程依賴於根據同位素類型和標記位點客製化的高純度標記標準品。製造商客製化用於細胞培養摻入、內標和成像應用的分子。液相層析串聯質譜 (LC-MS/MS) 和碎片分析中分析儀器和軟體的進步，推動了對穩定同位素標準品的需求。

生產和客製化平台是否提高了可用性？

該公司正在擴大生物合成（利用標記前體的微生物發酵）、化學合成和酶促生物轉化工藝，以生產高純度同位素。新平台支援位點特異性標記和標記組合（例如雙13C-15N），從而實現詳細的代謝分析。採用快速層析法和高效液相層析的自動化純化系統可提高通量並降低成本。

最佳化的交付時間——快速客製化批次以滿足製藥公司的時間表——由數位訂購入口網站和樣品交付追蹤提供支援。專為藥物代謝研究和微生物通量評估量身定做的多同位素試劑套件正在推動CRO和生物製造商的採用。

為什麼研究者要跨領域整合這些工具？

定量生物學家和藥理學家利用同位素標記標準品進行絕對濃度測量、清除率分析和藥物間相互作用研究。系統生物學家使用標記前驅物追蹤天然產物的生物合成途徑。作物和環境研究人員使用標記代謝物追蹤土壤-植物系統中的吸收和轉化。在臨床營養研究中，穩定同位素液體示蹤劑可以非侵入性地追蹤吸收和代謝過程。監管機構要求在品管實驗室中使用標記內標進行測定驗證和批次放行測試。

是什麼推動了穩定同位素標記生物分子市場的成長？

穩定同位素標記生物分子市場的成長受到與研究精度、生產可擴展性和跨學科應用相關的多種因素的驅動。發酵和化學標記方法的進步正在降低成本並擴大複雜同位素的可用性。全球對蛋白質體學、代謝體學和藥物研發管線的投資不斷增加，支持了對高品質參考材料的需求。客製化的短期合成和承包標準試劑套件可滿足合約研究組織 (CRO)、生物製藥公司和學術機構的時間表。監管機構對藥品和食品安全檢測中準確定量的期望也在推動其廣泛應用。此外，儀器供應商和同位素供應商之間的夥伴關係實現了整合工作流程，將標記參考材料與樣品製備、分析和軟體相結合，從而加快了獲得結果的時間並提高了研究品質。

部分

模式種（D標記生物分子、15N標記生物分子、13C標記生物分子）；最終用戶（科研、醫療）

受訪公司範例

  • Alsachim
  • BOC Sciences
  • Cambridge Isotope Laboratories
  • CDN Isotopes
  • Cerilliant Corporation
  • Entegris（IsoSciences）
  • Eurisotop
  • Ionetix
  • IsoFlex
  • IsoLife BV
  • JSC Isotope
  • LGC Standards
  • Lumiprobe
  • Medical Isotopes, Inc.
  • Merck KGaA（Sigma-Aldrich）
  • NIST
  • Nordion（Canada）, Inc.
  • Omicron Biochemicals, Inc.
  • PerkinElmer, Inc.
  • Silantes

人工智慧整合

我們正在利用有效的專家內容和人工智慧工具來改變市場和競爭情報。

Global 特定產業產業SLM 的典型規範，而是建立了一個從世界各地專家收集的內容庫，包括影片錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP38103

Global Stable Isotope Labeled Biomolecules Market to Reach US$517.0 Million by 2030

The global market for Stable Isotope Labeled Biomolecules estimated at US$371.1 Million in the year 2024, is expected to reach US$517.0 Million by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. D Labeled Biomolecules, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$308.0 Million by the end of the analysis period. Growth in the 15N Labeled Biomolecules segment is estimated at 6.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$97.6 Million While China is Forecast to Grow at 5.5% CAGR

The Stable Isotope Labeled Biomolecules market in the U.S. is estimated at US$97.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$82.9 Million by the year 2030 trailing a CAGR of 5.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.0% and 4.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Stable Isotope Labeled Biomolecules Market - Key Trends & Drivers Summarized

What’s Driving Growth in Stable Isotope Labeled Biomolecules for Research?

Stable isotope labeled biomolecules-such as ¹³C, ¹5N, ²H labeled amino acids, nucleotides, lipids, and metabolites-are critical tools in proteomics, metabolomics, pharmacokinetics, and tracer studies. Used in mass spectrometry assays, isotope dilution quantification, MRI imaging agents, cell tracing experiments, and metabolic flux analysis. Major end-users include academic labs, pharma R&D, biomanufacturing QC, and petrochemical testing.

Complex workflows-accurate quantification, pathway mapping, quality assurance-depend on access to high-purity labeled standards customized by isotope type and labeling sites. Manufacturers tailor molecules for cell-culture incorporation, internal standardization, and imaging applications. Analytical instrumentation and software advancements in LC-MS/MS and fragment analysis have elevated demand for robust isotopic standards.

Are Production & Customization Platforms Advancing Availability?

Companies are scaling biosynthesis (microbial fermentation with labeled precursors), chemical synthesis, and enzymatic biotransformations to produce high-purity isotopologues. New platforms support site-specific labeling and multiple-label combinations (e.g., dual ¹³C-¹5N), enabling fine-grained metabolic analysis. Automated purification systems using flash chromatography and HPLC increase throughput and reduce costs.

Turn-around optimization-rapid custom batches for pharma timelines-is supported by digital ordering portals and sample delivery tracking. Multi-isotope kits tailored for drug metabolism studies and microbial flux assessments are boosting usage in CROs and biomanufacturers.

Why Are Researchers Integrating These Tools Across Disciplines?

Quantitative biologists and pharmacologists rely on isotope-labeled standards for absolute concentration measurement, clearance profiling, and drug-drug interaction studies. Systems biologists track natural-product biosynthesis pathways using labeled precursors. Crop and environmental researchers use labeled metabolites to trace uptake and transformation in soil-plant systems. Stable isotope liquid tracers in clinical nutritional studies supply non-invasive tracking of absorption and metabolic fate. Regulatory bodies require labeled internal standards for assay validation and batch release tests in QC labs.

What’s Powering the Growth in the Stable Isotope Labeled Biomolecules Market?

The growth in the stable isotope labeled biomolecules market is driven by several factors related to research precision, production scalability, and interdisciplinary adoption. Advances in fermentation and chemical-labeling methods are reducing costs and expanding availability of complex isotopologues. Increasing global investment in proteomics, metabolomics, and drug pipelines supports demand for high-quality standards. Customized, short-run synthesis and turnkey standard kits meet CRO, biopharma, and academic timelines. Regulatory expectations for precise quantification in drug and food safety assays support widespread adoption. Additionally, partnerships between instrument vendors and isotope suppliers enable integrated workflows-combining labeled standards with sample prep, analytics, and software-accelerating time-to-result and research quality.

SCOPE OF STUDY:

The report analyzes the Stable Isotope Labeled Biomolecules market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (D Labeled Biomolecules, 15N Labeled Biomolecules, 13C Labeled Biomolecules); End-Use (Scientific Research End-Use, Medical End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 37 Featured) -

  • Alsachim
  • BOC Sciences
  • Cambridge Isotope Laboratories
  • CDN Isotopes
  • Cerilliant Corporation
  • Entegris (IsoSciences)
  • Eurisotop
  • Ionetix
  • IsoFlex
  • IsoLife BV
  • JSC Isotope
  • LGC Standards
  • Lumiprobe
  • Medical Isotopes, Inc.
  • Merck KGaA (Sigma-Aldrich)
  • NIST
  • Nordion (Canada), Inc.
  • Omicron Biochemicals, Inc.
  • PerkinElmer, Inc.
  • Silantes

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Stable Isotope Labeled Biomolecules - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growth in Proteomics and Metabolomics Research Drives Demand for Labeled Biomolecules
    • Rising Adoption of Mass Spectrometry in Life Sciences Propels Use of Stable Isotopes
    • Personalized Medicine and Targeted Drug Development Expand Addressable Research Applications
    • Regulatory Emphasis on Quantitative Bioanalysis Strengthens Business Case for Labeled Standards
    • Increase in Biopharma R&D Budgets Accelerates Demand for High-Purity Stable Isotope Compounds
    • Expansion of Clinical Diagnostics and Biomarker Discovery Spurs Usage in Preclinical Studies
    • Growth in Academic-Industry Collaborations Facilitates Commercial Availability of Custom Molecules
    • Technological Advancements in Labeling Techniques Improve Accuracy and Yield
    • Adoption of Isotope Dilution Techniques in Environmental and Food Testing Broadens Market Scope
    • Outsourcing Trends in Drug Discovery Boost Demand for Third-Party Stable Isotope Services
    • Rising Complexity of Biotherapeutics Drives Requirement for Multi-Isotopic Labeling
    • Globalization of CROs and CDMOs Expands Supply Chain for Labeled Biomolecule Manufacturing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Stable Isotope Labeled Biomolecules Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Stable Isotope Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Stable Isotope Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for D Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for D Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for D Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for 15N Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for 15N Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for 15N Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for 13C Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for 13C Labeled Biomolecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for 13C Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Scientific Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Scientific Research End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Scientific Research End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Medical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Medical End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Medical End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • JAPAN
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • CHINA
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • EUROPE
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Stable Isotope Labeled Biomolecules by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • FRANCE
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • GERMANY
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Stable Isotope Labeled Biomolecules Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Stable Isotope Labeled Biomolecules by Type - D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Stable Isotope Labeled Biomolecules by Type - Percentage Breakdown of Value Sales for D Labeled Biomolecules, 15N Labeled Biomolecules and 13C Labeled Biomolecules for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Stable Isotope Labeled Biomolecules by End-Use - Scientific Research End-Use and Medical End-Use Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Stable Isotope Labeled Biomolecules by End-Use - Percentage Breakdown of Value Sales for Scientific Research End-Use and Medical End-Use for the Years 2014, 2025 & 2030

IV. COMPETITION